Company intelligence / Profile preview

nanoPET Pharma

Ownership: Private
Employees: ~10
Development stage: Other

Overview

nanoPET Pharma develops and markets innovative diagnostic imaging agents. Its Viscover™ portfolio covers preclinical MRI, CT, ultrasound and optical imaging. The company also pursues clinical development of patented inorganic nanoparticle PET tracers. Through its subsidiary Xiralite it supplies medical devices for rheumatic disease diagnostics. Some products are commercially available; others are in preclinical or early clinical stages.

Therapeutic areas: NeurologyOncologyOtherRheumatologyCardiovascular
Modalities: NanoparticleRadiopharmaceutical (including PET/SPECT tracers)Small molecule (for some imaging agents)Contrast agent
Industry: Medical Imaging

Partnerships

Not specifically listed in public sources.

Beyond the preview

Go deeper on nanoPET Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nanoPET Pharma.

Explore the full profile